5,167 Charles River Laboratories International, Inc. $CRL Shares Purchased by Sterling Capital Management LLC

Sterling Capital Management LLC raised its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 350.3% during the 3rd quarter, Holdings Channel.com reports. The firm owned 6,642 shares of the medical research company’s stock after buying an additional 5,167 shares during the period. Sterling Capital Management LLC’s holdings in Charles River Laboratories International were worth $1,959,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Physician Wealth Advisors Inc. increased its stake in Charles River Laboratories International by 127.9% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 98 shares of the medical research company’s stock worth $29,000 after acquiring an additional 55 shares during the period. Continuum Advisory LLC bought a new stake in shares of Charles River Laboratories International during the 2nd quarter valued at $30,000. IFP Advisors Inc grew its stake in Charles River Laboratories International by 182.8% during the third quarter. IFP Advisors Inc now owns 164 shares of the medical research company’s stock worth $48,000 after buying an additional 106 shares in the last quarter. Compass Wealth Management LLC acquired a new position in Charles River Laboratories International during the third quarter valued at approximately $69,000. Finally, Activest Wealth Management boosted its holdings in shares of Charles River Laboratories International by 25.9% in the 3rd quarter. Activest Wealth Management now owns 277 shares of the medical research company’s stock valued at $82,000 after purchasing an additional 57 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, CEO Birgit Girshick sold 6,500 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total value of $1,819,350.00. Following the completion of the transaction, the chief executive officer directly owned 36,013 shares in the company, valued at approximately $10,080,038.70. This trade represents a 15.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Victoria Creamer sold 4,179 shares of Charles River Laboratories International stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $259.16, for a total value of $1,083,029.64. Following the sale, the executive vice president directly owned 30,051 shares in the company, valued at $7,788,017.16. The trade was a 12.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 94,127 shares of company stock worth $26,776,516 over the last three months. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Stock Performance

Shares of Charles River Laboratories International stock opened at $345.08 on Monday. The company’s 50 day moving average price is $294.35 and its two-hundred day moving average price is $233.67. The firm has a market capitalization of $16.47 billion, a P/E ratio of -71.15, a P/E/G ratio of 3.23 and a beta of 1.40. Charles River Laboratories International, Inc. has a fifty-two week low of $146.20 and a fifty-two week high of $351.21. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.25. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $980.53 million. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The company’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period in the prior year, the business earned $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, equities analysts forecast that Charles River Laboratories International, Inc. will post 11.38 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CRL has been the topic of several recent analyst reports. UBS Group assumed coverage on Charles River Laboratories International in a research note on Wednesday, September 30th. They issued a “buy” rating and a $357.00 price target on the stock. Citigroup reaffirmed a “buy” rating on shares of Charles River Laboratories International in a research note on Wednesday, July 8th. Deutsche Bank Aktiengesellschaft lifted their target price on Charles River Laboratories International from $300.00 to $320.00 and gave the company a “buy” rating in a research report on Friday, September 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Charles River Laboratories International in a research note on Monday, September 28th. Finally, Barclays increased their target price on shares of Charles River Laboratories International from $300.00 to $330.00 and gave the stock an “overweight” rating in a report on Friday, September 25th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Charles River Laboratories International currently has an average rating of “Moderate Buy” and a consensus target price of $302.33.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.